Industry News
Biotechnology Industry News
Pfizer on Monday unveiled seven…
Pfizer on Monday unveiled seven near-term trials of its PD-1xVEGF bispecific antibody, the first of what chief oncology officer Jeff Legos, Ph.D., called “many planned waves” of clinical investigation into the asset. These include a
Novo Nordisk has reported the…
Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market served by Alnylam, BridgeBio and Pfizer.
As Neuphoria Therapeutics…
As Neuphoria Therapeutics considers its options in the wake of the failure of its phase 3 social anxiety program, an investor has swooped in with one potential escape route.
Another of the psychiatry drugs…
Another of the psychiatry drugs Neurocrine licensed from Takeda has stumbled in the clinic.
CeleCor presented the results of…
CeleCor presented the results of its pivotal CeleBrate phase 3 trial in a late-breaking session at the the American Heart Association’s annual scientific sessions.
Voyager Therapeutics is shoving…
Voyager Therapeutics is shoving off on a new journey to discover and develop small molecules targeting protein bundles that contribute to neurodegenerative diseases. Voyager is paying travel partner Transition Bio a single-digit million-dollar upfront payment,
Cogent Biosciences has cleared…
Cogent Biosciences has cleared another phase 3 hurdle for its lead asset, bezuclastinib, teeing up an FDA approval in submission for a gastrointestinal cancer in the first half of next year.
Iambic will use the funds to…
Iambic will use the funds to continue its recent pipeline progress with a focus on bringing two of its programs to the clinic.
Merck & Co.’s PCSK9-targeted…
Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions similar to those observed with existing injectables.
AnaptysBio has abandoned plans to…
AnaptysBio has abandoned plans to develop rosnilimab for ulcerative colitis after the PD-1 agonist flunked a phase 2 study.
In a licensing deal unveiled…
In a licensing deal unveiled Monday, Lyell Immunopharma is handing over $40 million in cash and almost 2 million of its shares to secure rights to a phase 1-stage CAR-T cell therapy for colorectal cancer.
Roche has reported wins for its…
Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 multiple sclerosis trials. One victory was based on the finding that the candidate was non-inferior to Ocrevus, despite the company
AstraZeneca’s aldosterone synthase…
AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said in a first look at the data from a key phase 3 win.
The FDA has put a clinical hold on…
The FDA has put a clinical hold on a Tenaya Therapeutics gene therapy study while the biotech works to standardize activities related to the immunosuppression regimen across trial sites.
Eli Lilly has penned a research…
Eli Lilly has penned a research pact worth $1.2 billion in biobucks with SanegeneBio to help pinpoint cardiometabolic RNAi medicines at the correct tissues.
After a chaotic and fierce bidding…
After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has prevailed in its pursuit of obesity biotech Metsera.
MeiraGTx is cashing in on a gene…
MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the program to Eli Lilly in a deal potentially worth more than $475 million.
Amid Novo Nordisk and Pfizer’s…
Amid Novo Nordisk and Pfizer’s whiplash bidding war for obesity biotech Metsera, Novo’s CEO has, quite literally, told its rival to put its money where its mouth is.
Sana Biotechnology, CAMP4…
Sana Biotechnology, CAMP4 Therapeutics and Crinetics Pharmaceuticals have all used the third quarter to refocus their pipelines on the most promising candidates.
The patient who was hospitalized…
The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. Both phase 3 studies of the candidate remain on hold as the biotech works to understand liver-related events seen in the